Stoke Therapeutics, Inc. $STOK is Checkpoint Capital L.P.'s 7th Largest Position

Key Points

• Checkpoint Capital L.P. significantly increased its stake in Stoke Therapeutics, Inc. by 139.3% to hold 730,717 shares, making it the 7th largest position in its portfolio.
• Insider trading activity revealed that Barry Ticho and Edward M. Md Kaye sold shares, resulting in a decrease of 22.95% and 33.43% in their ownership, respectively.
• Brokerage firms have raised their price targets on Stoke Therapeutics, with Wedbush and BTIG Research setting new targets of $22.00 and $28.00, respectively.

Checkpoint Capital L.P. increased its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 139.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 730,717 shares of the company's stock after acquiring an additional 425,330 shares during the quarter. Stoke Therapeutics makes up 2.7% of Checkpoint Capital L.P.'s portfolio, making the stock its 7th biggest position. Checkpoint Capital L.P. owned 1.34% of Stoke Therapeutics worth $4,859,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in Stoke Therapeutics by 1,842.0% during the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after buying an additional 5,084 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Stoke Therapeutics by 123.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock worth $1,053,000 after purchasing an additional 52,813 shares during the last quarter. ProShare Advisors LLC bought a new position in Stoke Therapeutics in the 4th quarter worth approximately $139,000. XTX Topco Ltd bought a new position in Stoke Therapeutics in the 1st quarter worth approximately $267,000. Finally, Millennium Management LLC grew its holdings in Stoke Therapeutics by 417.9% in the 4th quarter. Millennium Management LLC now owns 76,829 shares of the company's stock worth $847,000 after buying an additional 61,994 shares in the last quarter.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 5,501 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total value of $109,304.87. Following the sale, the insider directly owned 18,469 shares of the company's stock, valued at approximately $366,979.03. This trade represents a 22.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 45,996 shares of the firm's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $20.13, for a total value of $925,899.48. Following the completion of the sale, the director directly owned 91,585 shares in the company, valued at approximately $1,843,606.05. This represents a 33.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 107,719 shares of company stock worth $2,063,359 over the last three months. Corporate insiders own 9.50% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on STOK. Wedbush increased their price objective on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. BTIG Research set a $28.00 price objective on Stoke Therapeutics and gave the stock a "buy" rating in a report on Monday, August 18th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. HC Wainwright decreased their price target on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Jefferies Financial Group started coverage on Stoke Therapeutics in a research note on Friday, July 18th. They set a "buy" rating and a $30.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $25.57.

Stoke Therapeutics Stock Up 0.9%

Shares of Stoke Therapeutics stock opened at $19.77 on Thursday. The stock has a market cap of $1.08 billion, a PE ratio of 23.26 and a beta of 1.14. The business has a fifty day simple moving average of $14.58 and a 200-day simple moving average of $10.89. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $20.45.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. The business had revenue of $13.82 million during the quarter, compared to analysts' expectations of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. Analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.